Therapeutics: Glycogen synthase kinase 3β (GSK3B); ubiquitin specific peptidase 22 (USP22); lysine-specific demethylase 1 (LSD1; KDM1A)


INDICATION: Brain cancer

Patient sample and mouse studies suggest that inhibiting the GSK3β-USP22-LSD1 axis could help treat glioblastoma multiforme (GBM) and other brain

Read the full 220 word article

How to gain access

Continue reading with a
two-week free trial.